Alvotech turns to net loss of USD 65.79 million for six months ended June 30, 2026; revenue falls 31% to USD 211.64 million

Alvotech posted a loss for the six months ended June 30, 2026 of USD 65.79 million, swinging from profit a year earlier. Revenue fell 31% to USD 211.64 million, with product and service revenue down 48% to USD 105.94 million. Operating result turned to a loss of USD 2.03 million, while general and administrative expenses climbed 53% to USD 69.23 million. Cash and cash equivalents totaled USD 142.75 million at June 30, 2026, with total borrowings of USD 1.31 billion. Resubmitted FDA BLAs for AVT05 and AVT06, and guided 2026 total revenue of USD 650 million to USD 700 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein. (C)